We are live on
!
Find out more
EI
EAM Investors Portfolio holdings
AUM
$866M
1-Year Est. Return
377.14%
This Fund
S&P 500
This Quarter
Est. Return
+113.09%
1 Year Est. Return
+377.14%
3 Year Est. Return
+5,228.32%
5 Year Est. Return
+49,813.07%
10 Year Est. Return
+19,957,621.5%
AUM
$452M
AUM Growth
+$130M
(+40%)
Cap. Flow
-$18.5M
Cap. Flow
% of AUM
-4.08%
Top 10 Holdings %
Top 10 Hldgs %
10.66%
Holding
352
New
147
Increased
15
Reduced
84
Closed
97
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AWH
Aspira Women's Health Inc. Common Stock
AWH
|
+$3.03M |
| 2 |
OneSpan
OSPN
|
+$2.96M |
| 3 |
Anterix
ATEX
|
+$2.79M |
| 4 |
Calix
CALX
|
+$2.73M |
| 5 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
+$2.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$3.54M |
| 2 |
Karyopharm Therapeutics
KPTI
|
+$3.44M |
| 3 |
Teladoc Health
TDOC
|
+$3.2M |
| 4 |
Krystal Biotech
KRYS
|
+$3M |
| 5 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
+$2.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.95% |
| 2 | Technology | 21.89% |
| 3 | Consumer Discretionary | 16.2% |
| 4 | Industrials | 10.05% |
| 5 | Consumer Staples | 6.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
STEX
251
Streamex Corp
STEX
$75.3M
| $489K | 0.11% |
+6,795
| New | +$591K |
|
|
IMDX
252
Insight Molecular Diagnostics
IMDX
$155M
| $462K | 0.1% |
+12,088
| New | +$624K |
|
253
Mammoth Energy Services
TUSK
$142M
| $348K | 0.08% |
+295,107
| New | +$342K |
|
254
Perspective Therapeutics
CATX
$339M
| $172K | 0.04% |
31,010
-77,095
| -71% | -$496K |
|
255
Arcosa
ACA
$7.12B
| – | – |
-42,968
| Closed | -$1.71M |
|
256
Agilysys
AGYS
$3.03B
| – | – |
-95,973
| Closed | -$1.6M |
|
|
AMED
257
DELISTED
Amedisys
AMED
| – | – |
-14,581
| Closed | -$2.68M |
|
258
AMN Healthcare
AMN
$1.19B
| – | – |
-20,972
| Closed | -$1.21M |
|
259
Aprea Therapeutics
APRE
$7.83M
| – | – |
-3,406
| Closed | -$2.37M |
|
260
Ares Management
ARES
$31.2B
| – | – |
-46,822
| Closed | -$1.45M |
|
261
Aspen Aerogels
ASPN
$571M
| – | – |
-185,339
| Closed | -$1.14M |
|
|
BRT
262
BRT Apartments
BRT
$271M
| – | – |
-40,676
| Closed | -$417K |
|
263
CACI
CACI
$13.9B
| – | – |
-8,869
| Closed | -$1.87M |
|
264
Cogent Communications
CCOI
$546M
| – | – |
-30,904
| Closed | -$2.53M |
|
265
ClearPoint Neuro
CLPT
$408M
| – | – |
-136,525
| Closed | -$489K |
|
266
Cannae Holdings
CNNE
$652M
| – | – |
-50,157
| Closed | -$1.68M |
|
267
Cohu
COHU
$2.45B
| – | – |
-17,962
| Closed | -$222K |
|
268
Collegium Pharmaceutical
COLL
$944M
| – | – |
-101,067
| Closed | -$1.65M |
|
269
Cirrus Logic
CRUS
$6.19B
| – | – |
-20,909
| Closed | -$1.37M |
|
270
Crown Crafts
CRWS
$32.3M
| – | – |
-105,823
| Closed | -$506K |
|
271
Casella Waste Systems
CWST
$5.75B
| – | – |
-72,335
| Closed | -$2.83M |
|
272
DHT Holdings
DHT
$2.96B
| – | – |
-317,020
| Closed | -$2.43M |
|
273
Distribution Solutions Group
DSGR
$1.61B
| – | – |
-69,898
| Closed | -$934K |
|
274
eHealth
EHTH
$43.2M
| – | – |
-17,377
| Closed | -$2.45M |
|
275
Enphase Energy
ENPH
$5.24B
| – | – |
-49,889
| Closed | -$1.61M |
|
Similar funds
RWM
MCM
HP
OMG
ICCFIA
WFAL
WCM
TSS
EAM Investors's Q2 2020 Portfolio in Review
As of Q2 2020, EAM Investors held 352 positions worth $452M, up 40% from $322M the previous quarter. Its ten largest holdings account for 11% of the portfolio.
EAM Investors withdrew a net $18.5M in Q2 2020, closing 97 positions and reducing 84 holdings. Its most notable exit was Karyopharm Therapeutics, an estimated $3.44M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 40% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, EAM Investors opened a new position in Aspira Women's Health Inc. Common Stock worth $2.61M.
- EAM Investors's largest Q2 2020 buy was Aspira Women's Health Inc. Common Stock: 45,313 shares worth $2.61M.
- EAM Investors added most to Purple Innovation in Q2 2020, an estimated $2.04M increase.
- EAM Investors's biggest Q2 2020 reduction was Axsome Therapeutics, cutting an estimated $3.54M.
- EAM Investors fully exited Karyopharm Therapeutics in Q2 2020, selling an estimated $3.44M.
- EAM Investors's ten largest holdings make up 11% of its $452M portfolio in Q2 2020.
- EAM Investors opened 147 new positions and closed 97 in Q2 2020.
- EAM Investors's portfolio value rose 40% quarter-over-quarter to $452M.
Based on EAM Investors's 13F filing for Q2 2020, filed 13 Aug 2020.